-
2024-514404-13-00
5
2020-10-01
Atopic Dermatitis
-
2022-502201-16-00
4
2020-09-30
Relapsed/refractory chronic lymphocytic leukemia
-
2022-502841-91-00
5
2020-08-12
Crohn’s Disease
-
2023-509394-23-00
5
2020-06-12
Stage II melanoma arising from a primary cutaneous site after surgery
-
2024-516271-32-00
5
2020-06-03
Adenocarcinoma of the gastroesophageal junction (AEG type I-III)
-
2023-505042-25-00
5
2020-05-05
Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
-
2024-511577-29-01
5
2020-03-13
intermediate and high-risk rectal cancer
-
2024-511653-22-00
5
2020-02-12
Cutaneous Squamous Cell Carcinoma (CSCC)
-
2024-513914-36-00
4
2019-12-17
locally-advanced Anal Carcinoma, Anal cancer stage II and III
-
2023-506551-23-00
5
2019-11-21
Recurrent or primary advanced (Stage III or IV) endometrial cancer
-
2023-507582-25-00
5
2019-08-02
Malignant Extracranial Germ Cell Tumours (MGCT)
-
2023-504930-23-00
5
2019-07-19
Episodic Migraine
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2022-502937-24-00
5
2019-01-02
Atopic Dermatitis
-
2023-506994-36-00
5
2018-10-11
Ulcerative Colitis
-
2022-501966-23-00
5
2018-09-11
Resected High-Risk Stage II Melanoma
-
2024-514945-12-00
10
2018-09-03
locally advanced resectable adenocarcinoma of the oesophagogastric
jun
-
2024-515783-31-00
5
2018-08-24
Newly Diagnosed Multiple Myeloma
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2023-504820-24-00
5
2018-03-21
Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-504951-29-00
5
2017-07-27
Chron's Disease
-
2023-505509-18-00
5
2017-07-12
mature aggressive B-cell lymphoma and leukemia in children and adolesc